In addition, these results further emphasise the view that kallikrein 6 and kallikrein 10 have the potential to become novel cancer markers for early diagnosis and/or monitoring of USPC, as well as possible immunotherapeutic targets of vaccination strategies against recurrent/refractory serous papillary gynecologic tumours (Cannon et al, 2002). This evidence concerns the gene KLK6 and cancer.